PCN243 COST-MINIMIZATION OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.438
https://www.valueinhealthjournal.com/article/S1098-3015(19)32816-5/fulltext
Title :
PCN243 COST-MINIMIZATION OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32816-5&doi=10.1016/j.jval.2019.09.438
First page :
Section Title :
Open access? :
No
Section Order :
10368